Safety follow-up for GT005 in geographic eye damage
Part of Eyes & vision, Skin clinical trials.
This study checks the long-term safety of GT005, a treatment you received in an earlier study, for geographic atrophy related to age-related macular degeneration. It mainly asks you to come to follow-up visits and confirm how you are doing over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a consent form (written permission) and you agree to join
- You received GT005 before in one of the earlier Gyroscope studies (GT005-01, GT005-02, or GT005-03)
- You are willing to return for scheduled study visits
- You agree to complete the study procedures at those visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests dimethyl fumarate (Tecfidera) to slow the growth of geographic atrophy, a form of age-related macular degeneration that affects central vision. You may be asked to take the study medicine and attend regular eye scans over about 2 years to see if it helps.
This trial tests a new treatment called PST-611, a non-viral gene therapy given as an injection into the eye. It is for people aged 65 and older with a specific type of advanced dry age-related macular degeneration (AMD) called geographic atrophy, which has been getting worse over the past year.
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
This trial tests a daily eye drop (GAL-101) to see if it can slow the growth of geographic atrophy lesions in people with dry age-related macular degeneration (AMD) when the center of the macula is not yet involved.
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
Hear when a new Age Related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.